Mendra raised $82 million to apply artificial intelligence to the development of rare-disease drugs, accelerating discovery and commercialization.
treatment of primary CoQ10 deficiency
treatment of Duchenne muscular dystrophy
treatment of soft tissue sarcoma
treatment of myelodysplastic syndrome
treatment of idiopathic pulmonary fibrosis
treatment of vernal keratoconjunctivitis
treatment of esophageal cancer
